SMAD4 and NF1 mutations as potential biomarkers for poor prognosis to cetuximab-based therapy in Chinese metastatic colorectal cancer patients

SMAD4 and NF1 mutations as potential biomarkers for poor prognosis to cetuximab-based therapy in Chinese metastatic colorectal cancer patients

Abstract Background Cetuximab, an anti-EGFR monoclonal antibody, is used in combination with chemotherapy in clinic to enhance the outcome in metastatic colorectal cancer (mCRC) patients with only ~ 20% response rate. To date only activating mutations in KRAS and NRAS have been identified as poor pr...

Full description

Bibliographic Details
Main Authors: Zhu Mei, Yang W. Shao, Peinan Lin, Xiaomin Cai, Biao Wang, Yan Ding, Xiangyuan Ma, Xue Wu, Yewei Xia, Dongqin Zhu, Yongqian Shu, Zan Fu, Yanhong Gu
Format: Article
Language:English
Published: BMC 2018-04-01
Series:BMC Cancer
Subjects:
SMAD4
NF1
Metastatic colorectal cancer
Cetuximab
Prognosis
Next-generation sequencing
Online Access:http://link.springer.com/article/10.1186/s12885-018-4298-5

Internet

http://link.springer.com/article/10.1186/s12885-018-4298-5

Similar Items